What is the recommended post‑orchiectomy management for a healthy adult male with organ‑confined pure seminoma (stage I)?

Post-Orchiectomy Management for Organ-Confined Pure Seminoma (Stage I)

Active surveillance is the strongly preferred management strategy for stage I seminoma after orchiectomy, as 80-85% of patients are cured by orchiectomy alone and all relapses remain highly curable, sparing the majority from unnecessary treatment toxicity. 1, 2

Primary Management Options

Option 1: Active Surveillance (Strongly Preferred)

Surveillance should be offered as the preferred management option for compliant patients with available resources. 1, 2, 3

• Achieves 99% disease-specific survival while avoiding treatment-related toxicity in over 80% of patients 2
• Relapse rate is 15-20% overall, with higher risk (30-32%) in stage IB disease (tumor >4 cm or rete testis invasion) 1, 2, 3
• The 10-year relapse-free survival on surveillance is 93.4%, not significantly different from adjuvant radiotherapy 4
• Peak relapse risk occurs in the first 2 years, with 97% of relapses occurring in retroperitoneal or high iliac lymph nodes 2, 3

Surveillance Protocol Requirements:

Years 1-2:

• History, physical examination, and serum tumor markers (AFP, β-HCG, LDH) every 3-4 months 1
• Abdominal/pelvic CT every 6 months 1
• Chest radiographs only as clinically indicated 1

Years 3-4:

• History, physical, and markers every 6-12 months 1
• Abdominal/pelvic CT every 6-12 months in year 3, then annually in years 4-5 1

Year 5 and beyond:

• Annual follow-up with markers 1
• Patients should be informed of the <1% risk of late relapse after 5 years 1

Option 2: Adjuvant Carboplatin (Category 1 Alternative)

For patients who decline surveillance or for whom surveillance is not feasible, 1-2 cycles of carboplatin AUC × 7 is the preferred adjuvant treatment. 1

• Reduces relapse rate to 3-4% compared to 15-20% with surveillance 1, 3
• Demonstrates non-inferiority to radiotherapy with 5-year relapse-free rates of 94.7% versus 96% (HR 1.25, P=0.37) 1
• Significantly reduces contralateral testicular cancer risk: 2 cases with carboplatin versus 15 with radiotherapy (HR 0.22) 1
• Less toxic than radiotherapy with lower long-term morbidity 1, 3

Carboplatin Follow-up Protocol:

Year 1:

• History, physical, and markers every 3 months 1
• Annual abdominal/pelvic CT 1

Year 2:

• History, physical, and markers every 4 months 1
• Annual abdominal/pelvic CT 1

Year 3:

• History, physical, and markers every 6 months 1
• Annual abdominal/pelvic CT 1

Year 4 and beyond:

• Annual follow-up 1
• Risk of recurrence after 3 years is <0.3% annually 1

Option 3: Adjuvant Radiotherapy (Not Routinely Recommended)

Adjuvant radiotherapy should NOT be routinely administered and should be reserved only for highly selected patients unsuitable for surveillance with contraindications to chemotherapy. 1, 2, 3

• If radiotherapy is used, deliver 20 Gy in 10 daily 2.0-Gy fractions to infradiaphragmatic area including para-aortic lymph nodes 1
• Alternative dosing: 25.5 Gy in 17 fractions of 1.5 Gy each 1
• Avoid radiotherapy in patients with higher morbidity risk: history of pelvic surgery, horseshoe or pelvic kidney, inflammatory bowel disease, or prior radiotherapy 1
• Long-term toxicity concerns include secondary malignancies, cardiovascular disease, and bowel toxicity 1, 2, 3

Critical Decision-Making Algorithm

Step 1: Assess Patient Suitability for Surveillance

• Is the patient compliant and committed to long-term follow-up? 1
• Are resources available for regular CT imaging? 1
• Can the patient tolerate the 15-32% relapse risk knowing all relapses are curable? 2, 3

If YES → Proceed with active surveillance 1, 2

If NO → Proceed to Step 2

Step 2: Select Adjuvant Treatment

• Does the patient have contraindications to chemotherapy (severe renal impairment, hearing loss)? 1
• Does the patient have high-risk features for radiotherapy toxicity (pelvic surgery, inflammatory bowel disease)? 1

If chemotherapy acceptable → Offer 1-2 cycles carboplatin AUC × 7 1

If chemotherapy contraindicated AND no radiotherapy contraindications → Consider radiotherapy 1, 2

Management of Relapse

All relapses after surveillance are highly curable and should be treated according to stage at relapse. 1, 2

Stage IIA-B Relapse (lymph nodes 2-5 cm):

• Radiotherapy: Modified dog-leg fields, 30-36 Gy in 15-18 fractions 2, 3
• Alternative: 3 cycles BEP chemotherapy 1, 2

Stage IIC-III Relapse (lymph nodes >5 cm or distant metastases):

• 3 cycles BEP chemotherapy (bleomycin, etoposide, cisplatin) 1, 2, 3
• In patients >40 years, consider omitting bleomycin due to increased pneumonitis risk 2, 3
• Alternative: 4 cycles EP if bleomycin contraindicated 1

Common Pitfalls to Avoid

Do NOT use tumor size or rete testis invasion alone to mandate adjuvant treatment - these risk factors have not been consistently validated to override surveillance as the preferred option 2, 4

Do NOT routinely offer adjuvant radiotherapy - carboplatin and surveillance have superior risk-benefit profiles 1, 2, 3

Do NOT omit surveillance imaging in the first 3 years after adjuvant treatment - although relapse risk is <0.3% annually after 5 years, the first 3 years require annual abdominal/pelvic CT 1

Do NOT use mildly elevated β-HCG (<20 IU/L) or AFP (<20 ng/mL) alone to change management - other factors including hypogonadism and cannabis use can cause false-positive results 1

Do NOT perform routine chest CT or mediastinal radiotherapy - relapse rarely occurs at these sites 1